DCD IIT: Evaluating the Safety of Utilizing Donor Hearts From Donation After Circulatory Death (DCD) Donors
Evaluating the Safety of Utilizing Donor Hearts From Donation After Circulatory Death (DCD) Donors Compared to Donor Hearts From Donation After Brain Death (DBD) Donors: A Single Center Pilot Study
1 other identifier
interventional
30
1 country
1
Brief Summary
The purpose the research is to evaluate whether patients who receive a Donation after Circulatory Death (DCD) heart for cardiac transplantation using either normothermic regional perfusion (NRP) or direct procurement and perfusion (DPP) have similar outcomes as patients who receive Donation after Brain Death (DBD) heart using standard cold storage. The study will also evaluate whether DCD procured hearts have a meaningful impact on hearts available for transplantation at our center.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started May 2022
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 24, 2022
CompletedFirst Submitted
Initial submission to the registry
July 14, 2022
CompletedFirst Posted
Study publicly available on registry
July 18, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2025
CompletedApril 18, 2025
April 1, 2025
2.3 years
July 14, 2022
April 16, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Evaluate the safety of utilizing DCD donor hearts as compared to DBD donor hearts for transplantation.
Percentage of subjects with incidence of heart graft-related Serious Adverse Events (HGRSAEs) in the DCD Heart Transplanted Recipient Population
30 days post-heart transplant
Secondary Outcomes (1)
Assess the practical, financial and logistical viability of using NRP vs. DPP for the procurement of DCD donor hearts.
1 year
Study Arms (2)
DBD Donor Heart Transplantation
OTHERIf the heart offer is from a DBD donor, the heart will be retrieved per standard of care.
DCD Donor Heart Transplantation
OTHERIf the heart offer is from a DCD donor, the heart will be retrieved using one of two strategies: Normothermic Regional Perfusion (NRP) or Direct Procurement and Perfusion (DPP). NRP procedures will be used to procure all DCD hearts unless contraindicated or prohibited by the donor hospital. In the event the donor hospital does not allow NRP for cardiac organ procurement, or the target number of eight DCD transplants with NRP has been achieved, DPP with the Organ Care System (OCS) should be utilized.
Interventions
A technique of donor heart procurement.
A technique of donor heart procurement. The TransMedics' OCS Heart technology is the only portable system available for ex-vivo maintenance of the donor heart in a metabolically active and beating state. It is currently FDA approved for procurement and transport.
Eligibility Criteria
You may qualify if:
- Subjects must be willing and be capable of understanding the purpose and risks of the study and must sign a statement of informed consent OR consent of a legally authorized representative of a cognitively impaired individual will be obtained before the cognitively impaired individual may be included in research.
- Signed: 1) written informed consent document and 2) authorization to use and disclose protected health information
- Male or female, aged 18 years of age or older listed for primary heart transplant
You may not qualify if:
- Prior history of cardiac transplantation
- Multi-organ transplant
- Current or planned participation in another interventional trial
- Recipient has any condition that, in the opinion of the Investigator, would make study participation unsafe or would interfere with the objectives of the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Cedars Sinai Medical Center
Los Angeles, California, 90048, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Fardad Esmailian, MD
Cedars-Sinai Medical Center
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Surgical Director, Heart Transplantation and Mechanical Circulatory Support
Study Record Dates
First Submitted
July 14, 2022
First Posted
July 18, 2022
Study Start
May 24, 2022
Primary Completion
August 31, 2024
Study Completion
December 31, 2025
Last Updated
April 18, 2025
Record last verified: 2025-04